2 recruiting. 2 Phase 2, 1 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 2 | Recruiting 2 |
| Phase 1 | 1 | Recruiting 1 |
Follow Haploidentical Hematopoietic Stem Cell Transplant: new trials by email Literature Review of Haploidentical Hematopoietic Stem Cell Transplant trials Research Report on Haploidentical Hematopoietic Stem Cell Transplant
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Ruxolitinib-Enhanced Haplo HCT for Children and Young Adults With Sickle Cell Disease Ruxolitinib - Sickle Cell Disease, Hematopoetic Stem Cell Transplant | Phase 1 / Phase 2 | Recruiting | Arkansas Children's Hospital Research Institute | 24 | 2026-06-08 | 2026-06-04 |
| To Study Lower Dose of Cyclophosphamide After Stem Cell Transplant for Blood Cancers Cyclophosphamide - Haploidentical Hematopoietic Stem Cell Transplant, Hematological Malignancies | Phase 2 | Recruiting | Tata Memorial Centre | 20 | 2025-03-26 | 2026-07-22 |
Anemia, Sickle Cell (1) · Hematologic Neoplasms (1)
Hematologic Diseases (2) · Hemic and Lymphatic Diseases (2) · Anemia (1) · Anemia, Hemolytic (1) · Anemia, Hemolytic, Congenital (1) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (1) · Genetic Diseases, Inborn (1) · Hemoglobinopathies (1) · Neoplasms (1) · Neoplasms by Site (1)
Cyclophosphamide (1) · ruxolitinib (1)
Arkansas Children's Hospital Research Institute (1) · Tata Memorial Centre (1)
India (1) · United States (1)
PMID 11719388, PMID 11939602, PMID 11985515, PMID 12171484, PMID 14113077, PMID 1671578, PMID 18489989, PMID 19786984, PMID 2143514, PMID 22863841, PMID 22992668, PMID 25797174, PMID 26284307, PMID 2643045, PMID 31586477, PMID 32973350, PMID 33657221, PMID 34396331, PMID 3897863, PMID 4572127, PMID 4941317, PMID 6131300, PMID 8181080, PMID 8877390, PMID 9867758